Although Nogo-A's validity as a biomarker for ALS diagnosis/prognosis may need further confirmation, the above findings suggest Nogo and NgR could be potential targets for ALS adjunct therapy. This evidence concerns the gene RTN4 and amyotrophic lateral sclerosis.